nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolvaptan—ABCB1—esophageal cancer	0.747	1	CbGaD
Tolvaptan—Neurological symptom—Cisplatin—esophageal cancer	0.00659	0.0566	CcSEcCtD
Tolvaptan—Prothrombin level increased—Capecitabine—esophageal cancer	0.00357	0.0307	CcSEcCtD
Tolvaptan—Prurigo—Capecitabine—esophageal cancer	0.00318	0.0273	CcSEcCtD
Tolvaptan—Zafirlukast—PTGS1—esophageal cancer	0.0031	0.708	CrCbGaD
Tolvaptan—Deep vein thrombosis—Capecitabine—esophageal cancer	0.00241	0.0207	CcSEcCtD
Tolvaptan—Hyperuricaemia—Cisplatin—esophageal cancer	0.00214	0.0184	CcSEcCtD
Tolvaptan—Blood uric acid increased—Cisplatin—esophageal cancer	0.00203	0.0174	CcSEcCtD
Tolvaptan—Vaginal haemorrhage—Capecitabine—esophageal cancer	0.00198	0.017	CcSEcCtD
Tolvaptan—Hyperkalaemia—Cisplatin—esophageal cancer	0.00195	0.0168	CcSEcCtD
Tolvaptan—Ventricular fibrillation—Capecitabine—esophageal cancer	0.00191	0.0165	CcSEcCtD
Tolvaptan—Body temperature increased—Carboplatin—esophageal cancer	0.00191	0.0164	CcSEcCtD
Tolvaptan—Deep vein thrombosis—Methotrexate—esophageal cancer	0.00179	0.0154	CcSEcCtD
Tolvaptan—Polyuria—Cisplatin—esophageal cancer	0.00164	0.0141	CcSEcCtD
Tolvaptan—Blood bilirubin increased—Capecitabine—esophageal cancer	0.00155	0.0133	CcSEcCtD
Tolvaptan—Cerebrovascular accident—Cisplatin—esophageal cancer	0.00147	0.0127	CcSEcCtD
Tolvaptan—Pulmonary embolism—Capecitabine—esophageal cancer	0.00147	0.0126	CcSEcCtD
Tolvaptan—Hyponatraemia—Cisplatin—esophageal cancer	0.00145	0.0125	CcSEcCtD
Tolvaptan—Gastrointestinal haemorrhage—Cisplatin—esophageal cancer	0.00144	0.0124	CcSEcCtD
Tolvaptan—Blood creatinine increased—Cisplatin—esophageal cancer	0.00135	0.0116	CcSEcCtD
Tolvaptan—Dehydration—Cisplatin—esophageal cancer	0.00134	0.0115	CcSEcCtD
Tolvaptan—Ecchymosis—Capecitabine—esophageal cancer	0.00133	0.0114	CcSEcCtD
Tolvaptan—Urine output increased—Capecitabine—esophageal cancer	0.00133	0.0114	CcSEcCtD
Tolvaptan—Orthostatic hypotension—Cisplatin—esophageal cancer	0.00132	0.0113	CcSEcCtD
Tolvaptan—Breast disorder—Cisplatin—esophageal cancer	0.0013	0.0112	CcSEcCtD
Tolvaptan—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.0013	0.0112	CcSEcCtD
Tolvaptan—Vismodegib—ABCB1—esophageal cancer	0.00127	0.292	CrCbGaD
Tolvaptan—Polyuria—Capecitabine—esophageal cancer	0.00121	0.0104	CcSEcCtD
Tolvaptan—Hyperuricaemia—Methotrexate—esophageal cancer	0.00118	0.0101	CcSEcCtD
Tolvaptan—Thirst—Capecitabine—esophageal cancer	0.00112	0.00962	CcSEcCtD
Tolvaptan—Renal impairment—Capecitabine—esophageal cancer	0.00112	0.00962	CcSEcCtD
Tolvaptan—Blood uric acid increased—Methotrexate—esophageal cancer	0.00111	0.00956	CcSEcCtD
Tolvaptan—Respiratory failure—Methotrexate—esophageal cancer	0.00111	0.00956	CcSEcCtD
Tolvaptan—Renal failure—Cisplatin—esophageal cancer	0.00109	0.00941	CcSEcCtD
Tolvaptan—Pulmonary embolism—Methotrexate—esophageal cancer	0.00109	0.00939	CcSEcCtD
Tolvaptan—Cerebrovascular accident—Capecitabine—esophageal cancer	0.00109	0.00934	CcSEcCtD
Tolvaptan—Hyponatraemia—Capecitabine—esophageal cancer	0.00107	0.00919	CcSEcCtD
Tolvaptan—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.00106	0.00915	CcSEcCtD
Tolvaptan—Blood creatinine increased—Capecitabine—esophageal cancer	0.000997	0.00858	CcSEcCtD
Tolvaptan—Dehydration—Capecitabine—esophageal cancer	0.00099	0.00851	CcSEcCtD
Tolvaptan—Ecchymosis—Methotrexate—esophageal cancer	0.000987	0.00849	CcSEcCtD
Tolvaptan—Urine output increased—Methotrexate—esophageal cancer	0.000987	0.00849	CcSEcCtD
Tolvaptan—Urinary tract disorder—Cisplatin—esophageal cancer	0.000986	0.00848	CcSEcCtD
Tolvaptan—Connective tissue disorder—Cisplatin—esophageal cancer	0.000982	0.00844	CcSEcCtD
Tolvaptan—Urethral disorder—Cisplatin—esophageal cancer	0.000979	0.00842	CcSEcCtD
Tolvaptan—Orthostatic hypotension—Capecitabine—esophageal cancer	0.000972	0.00836	CcSEcCtD
Tolvaptan—Breast disorder—Capecitabine—esophageal cancer	0.000962	0.00827	CcSEcCtD
Tolvaptan—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.000958	0.00824	CcSEcCtD
Tolvaptan—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.000939	0.00807	CcSEcCtD
Tolvaptan—Cardiac disorder—Cisplatin—esophageal cancer	0.000927	0.00797	CcSEcCtD
Tolvaptan—Polyuria—Methotrexate—esophageal cancer	0.000902	0.00776	CcSEcCtD
Tolvaptan—Immune system disorder—Cisplatin—esophageal cancer	0.000902	0.00776	CcSEcCtD
Tolvaptan—Mediastinal disorder—Cisplatin—esophageal cancer	0.0009	0.00774	CcSEcCtD
Tolvaptan—Malnutrition—Cisplatin—esophageal cancer	0.00087	0.00748	CcSEcCtD
Tolvaptan—Hyperglycaemia—Capecitabine—esophageal cancer	0.00083	0.00714	CcSEcCtD
Tolvaptan—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000809	0.00695	CcSEcCtD
Tolvaptan—Ill-defined disorder—Cisplatin—esophageal cancer	0.000807	0.00694	CcSEcCtD
Tolvaptan—Renal failure—Capecitabine—esophageal cancer	0.000806	0.00693	CcSEcCtD
Tolvaptan—Malaise—Cisplatin—esophageal cancer	0.000784	0.00674	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000735	0.00632	CcSEcCtD
Tolvaptan—Discomfort—Cisplatin—esophageal cancer	0.000731	0.00629	CcSEcCtD
Tolvaptan—Urinary tract disorder—Capecitabine—esophageal cancer	0.000727	0.00625	CcSEcCtD
Tolvaptan—Connective tissue disorder—Capecitabine—esophageal cancer	0.000724	0.00622	CcSEcCtD
Tolvaptan—Urethral disorder—Capecitabine—esophageal cancer	0.000722	0.00621	CcSEcCtD
Tolvaptan—Breast disorder—Methotrexate—esophageal cancer	0.000716	0.00616	CcSEcCtD
Tolvaptan—Anaphylactic shock—Cisplatin—esophageal cancer	0.00071	0.0061	CcSEcCtD
Tolvaptan—Nervous system disorder—Cisplatin—esophageal cancer	0.000696	0.00599	CcSEcCtD
Tolvaptan—Skin disorder—Cisplatin—esophageal cancer	0.000689	0.00593	CcSEcCtD
Tolvaptan—Cardiac disorder—Capecitabine—esophageal cancer	0.000683	0.00588	CcSEcCtD
Tolvaptan—Anorexia—Cisplatin—esophageal cancer	0.000676	0.00582	CcSEcCtD
Tolvaptan—Angiopathy—Capecitabine—esophageal cancer	0.000668	0.00575	CcSEcCtD
Tolvaptan—Immune system disorder—Capecitabine—esophageal cancer	0.000665	0.00572	CcSEcCtD
Tolvaptan—Mediastinal disorder—Capecitabine—esophageal cancer	0.000664	0.00571	CcSEcCtD
Tolvaptan—Malnutrition—Capecitabine—esophageal cancer	0.000641	0.00551	CcSEcCtD
Tolvaptan—Dysgeusia—Capecitabine—esophageal cancer	0.000628	0.0054	CcSEcCtD
Tolvaptan—Decreased appetite—Cisplatin—esophageal cancer	0.000617	0.00531	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000613	0.00527	CcSEcCtD
Tolvaptan—Renal failure—Methotrexate—esophageal cancer	0.0006	0.00516	CcSEcCtD
Tolvaptan—Ill-defined disorder—Capecitabine—esophageal cancer	0.000595	0.00511	CcSEcCtD
Tolvaptan—Feeling abnormal—Cisplatin—esophageal cancer	0.000585	0.00503	CcSEcCtD
Tolvaptan—Malaise—Capecitabine—esophageal cancer	0.000578	0.00497	CcSEcCtD
Tolvaptan—Syncope—Capecitabine—esophageal cancer	0.000575	0.00494	CcSEcCtD
Tolvaptan—Loss of consciousness—Capecitabine—esophageal cancer	0.000563	0.00484	CcSEcCtD
Tolvaptan—Body temperature increased—Cisplatin—esophageal cancer	0.000561	0.00482	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000542	0.00466	CcSEcCtD
Tolvaptan—Urinary tract disorder—Methotrexate—esophageal cancer	0.000541	0.00466	CcSEcCtD
Tolvaptan—Discomfort—Capecitabine—esophageal cancer	0.000539	0.00464	CcSEcCtD
Tolvaptan—Urethral disorder—Methotrexate—esophageal cancer	0.000537	0.00462	CcSEcCtD
Tolvaptan—Dry mouth—Capecitabine—esophageal cancer	0.000534	0.00459	CcSEcCtD
Tolvaptan—Hypersensitivity—Cisplatin—esophageal cancer	0.000523	0.0045	CcSEcCtD
Tolvaptan—Shock—Capecitabine—esophageal cancer	0.000515	0.00443	CcSEcCtD
Tolvaptan—Nervous system disorder—Capecitabine—esophageal cancer	0.000513	0.00441	CcSEcCtD
Tolvaptan—Asthenia—Cisplatin—esophageal cancer	0.000509	0.00438	CcSEcCtD
Tolvaptan—Cardiac disorder—Methotrexate—esophageal cancer	0.000509	0.00437	CcSEcCtD
Tolvaptan—Skin disorder—Capecitabine—esophageal cancer	0.000508	0.00437	CcSEcCtD
Tolvaptan—Anorexia—Capecitabine—esophageal cancer	0.000499	0.00429	CcSEcCtD
Tolvaptan—Angiopathy—Methotrexate—esophageal cancer	0.000497	0.00428	CcSEcCtD
Tolvaptan—Immune system disorder—Methotrexate—esophageal cancer	0.000495	0.00426	CcSEcCtD
Tolvaptan—Mediastinal disorder—Methotrexate—esophageal cancer	0.000494	0.00425	CcSEcCtD
Tolvaptan—Diarrhoea—Cisplatin—esophageal cancer	0.000486	0.00418	CcSEcCtD
Tolvaptan—Malnutrition—Methotrexate—esophageal cancer	0.000477	0.0041	CcSEcCtD
Tolvaptan—Dysgeusia—Methotrexate—esophageal cancer	0.000467	0.00402	CcSEcCtD
Tolvaptan—Decreased appetite—Capecitabine—esophageal cancer	0.000455	0.00391	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000452	0.00388	CcSEcCtD
Tolvaptan—Constipation—Capecitabine—esophageal cancer	0.000447	0.00385	CcSEcCtD
Tolvaptan—Ill-defined disorder—Methotrexate—esophageal cancer	0.000443	0.00381	CcSEcCtD
Tolvaptan—Feeling abnormal—Capecitabine—esophageal cancer	0.000431	0.00371	CcSEcCtD
Tolvaptan—Malaise—Methotrexate—esophageal cancer	0.00043	0.0037	CcSEcCtD
Tolvaptan—Nausea—Cisplatin—esophageal cancer	0.000422	0.00363	CcSEcCtD
Tolvaptan—Body temperature increased—Capecitabine—esophageal cancer	0.000414	0.00356	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000403	0.00347	CcSEcCtD
Tolvaptan—Discomfort—Methotrexate—esophageal cancer	0.000401	0.00345	CcSEcCtD
Tolvaptan—AVPR1A—GPCR downstream signaling—AKAP13—esophageal cancer	0.000391	0.00295	CbGpPWpGaD
Tolvaptan—Anaphylactic shock—Methotrexate—esophageal cancer	0.000389	0.00335	CcSEcCtD
Tolvaptan—AVPR2—GPCR downstream signaling—AKAP13—esophageal cancer	0.000388	0.00293	CbGpPWpGaD
Tolvaptan—Hypersensitivity—Capecitabine—esophageal cancer	0.000385	0.00331	CcSEcCtD
Tolvaptan—Nervous system disorder—Methotrexate—esophageal cancer	0.000382	0.00328	CcSEcCtD
Tolvaptan—Skin disorder—Methotrexate—esophageal cancer	0.000378	0.00325	CcSEcCtD
Tolvaptan—Asthenia—Capecitabine—esophageal cancer	0.000375	0.00323	CcSEcCtD
Tolvaptan—CYP3A4—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.000373	0.00281	CbGpPWpGaD
Tolvaptan—Anorexia—Methotrexate—esophageal cancer	0.000371	0.00319	CcSEcCtD
Tolvaptan—Pruritus—Capecitabine—esophageal cancer	0.00037	0.00318	CcSEcCtD
Tolvaptan—AVPR1A—Signaling Pathways—KMT2D—esophageal cancer	0.000365	0.00275	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—KMT2D—esophageal cancer	0.000363	0.00273	CbGpPWpGaD
Tolvaptan—Diarrhoea—Capecitabine—esophageal cancer	0.000358	0.00308	CcSEcCtD
Tolvaptan—AVPR1A—GPCR downstream signaling—PDE4D—esophageal cancer	0.000358	0.0027	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—AKAP13—esophageal cancer	0.000355	0.00268	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—PDE4D—esophageal cancer	0.000355	0.00268	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—AKAP13—esophageal cancer	0.000353	0.00266	CbGpPWpGaD
Tolvaptan—CYP3A4—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.000346	0.00261	CbGpPWpGaD
Tolvaptan—Dizziness—Capecitabine—esophageal cancer	0.000346	0.00297	CcSEcCtD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—FKBP1A—esophageal cancer	0.000345	0.0026	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—GNG7—esophageal cancer	0.00034	0.00257	CbGpPWpGaD
Tolvaptan—Decreased appetite—Methotrexate—esophageal cancer	0.000339	0.00291	CcSEcCtD
Tolvaptan—AVPR2—GPCR downstream signaling—GNG7—esophageal cancer	0.000338	0.00255	CbGpPWpGaD
Tolvaptan—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000336	0.00289	CcSEcCtD
Tolvaptan—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.000334	0.00252	CbGpPWpGaD
Tolvaptan—Headache—Capecitabine—esophageal cancer	0.000328	0.00282	CcSEcCtD
Tolvaptan—AVPR1A—Signaling Pathways—ADCYAP1—esophageal cancer	0.000326	0.00246	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—PDE4D—esophageal cancer	0.000325	0.00245	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—ADCYAP1—esophageal cancer	0.000323	0.00244	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—PDE4D—esophageal cancer	0.000323	0.00243	CbGpPWpGaD
Tolvaptan—Feeling abnormal—Methotrexate—esophageal cancer	0.000321	0.00276	CcSEcCtD
Tolvaptan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.000318	0.0024	CbGpPWpGaD
Tolvaptan—ABCB1—HIF-1-alpha transcription factor network—HMOX1—esophageal cancer	0.000317	0.00239	CbGpPWpGaD
Tolvaptan—Nausea—Capecitabine—esophageal cancer	0.000311	0.00267	CcSEcCtD
Tolvaptan—AVPR1A—Signaling by GPCR—GNG7—esophageal cancer	0.000309	0.00233	CbGpPWpGaD
Tolvaptan—Body temperature increased—Methotrexate—esophageal cancer	0.000308	0.00265	CcSEcCtD
Tolvaptan—AVPR2—Signaling by GPCR—GNG7—esophageal cancer	0.000307	0.00231	CbGpPWpGaD
Tolvaptan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.000304	0.00229	CbGpPWpGaD
Tolvaptan—ABCB1—HIF-1-alpha transcription factor network—SMAD4—esophageal cancer	0.000304	0.00229	CbGpPWpGaD
Tolvaptan—CYP3A4—Tryptophan metabolism—CYP1B1—esophageal cancer	0.000304	0.00229	CbGpPWpGaD
Tolvaptan—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.0003	0.00226	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—CXCL2—esophageal cancer	0.0003	0.00226	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—WWOX—esophageal cancer	0.000298	0.00225	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—CXCL2—esophageal cancer	0.000298	0.00224	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—WWOX—esophageal cancer	0.000296	0.00223	CbGpPWpGaD
Tolvaptan—Hypersensitivity—Methotrexate—esophageal cancer	0.000287	0.00247	CcSEcCtD
Tolvaptan—CYP3A4—Tryptophan metabolism—CYP19A1—esophageal cancer	0.000285	0.00215	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—FKBP1A—esophageal cancer	0.000283	0.00214	CbGpPWpGaD
Tolvaptan—AVPR2—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000282	0.00213	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—FKBP1A—esophageal cancer	0.000281	0.00212	CbGpPWpGaD
Tolvaptan—Asthenia—Methotrexate—esophageal cancer	0.000279	0.0024	CcSEcCtD
Tolvaptan—AVPR1A—GPCR downstream signaling—ANXA1—esophageal cancer	0.000279	0.0021	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—WIF1—esophageal cancer	0.000277	0.00209	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—ANXA1—esophageal cancer	0.000277	0.00209	CbGpPWpGaD
Tolvaptan—Pruritus—Methotrexate—esophageal cancer	0.000276	0.00237	CcSEcCtD
Tolvaptan—AVPR2—Signaling Pathways—WIF1—esophageal cancer	0.000275	0.00207	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—CXCL2—esophageal cancer	0.000272	0.00205	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—SST—esophageal cancer	0.000271	0.00204	CbGpPWpGaD
Tolvaptan—AVPR2—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.000271	0.00204	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—CXCL2—esophageal cancer	0.00027	0.00204	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—SST—esophageal cancer	0.000269	0.00203	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—BBC3—esophageal cancer	0.000268	0.00202	CbGpPWpGaD
Tolvaptan—Diarrhoea—Methotrexate—esophageal cancer	0.000266	0.00229	CcSEcCtD
Tolvaptan—AVPR1A—GPCR downstream signaling—GHRL—esophageal cancer	0.000264	0.00199	CbGpPWpGaD
Tolvaptan—CYP3A4—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000262	0.00198	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—GHRL—esophageal cancer	0.000262	0.00198	CbGpPWpGaD
Tolvaptan—Dizziness—Methotrexate—esophageal cancer	0.000258	0.00221	CcSEcCtD
Tolvaptan—AVPR1A—Signaling Pathways—CSNK1A1—esophageal cancer	0.000256	0.00193	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CSNK1A1—esophageal cancer	0.000254	0.00191	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—ANXA1—esophageal cancer	0.000253	0.00191	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—ANXA1—esophageal cancer	0.000251	0.00189	CbGpPWpGaD
Tolvaptan—ABCB1—HIF-1-alpha transcription factor network—HIF1A—esophageal cancer	0.000249	0.00187	CbGpPWpGaD
Tolvaptan—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000247	0.00186	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—SST—esophageal cancer	0.000246	0.00186	CbGpPWpGaD
Tolvaptan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000245	0.00185	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—SST—esophageal cancer	0.000245	0.00184	CbGpPWpGaD
Tolvaptan—Headache—Methotrexate—esophageal cancer	0.000244	0.0021	CcSEcCtD
Tolvaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—esophageal cancer	0.000242	0.00183	CbGpPWpGaD
Tolvaptan—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000242	0.00183	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—GHRL—esophageal cancer	0.00024	0.00181	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—PFN1—esophageal cancer	0.000239	0.0018	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—GHRL—esophageal cancer	0.000238	0.0018	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—PFN1—esophageal cancer	0.000237	0.00179	CbGpPWpGaD
Tolvaptan—AVPR1A—G alpha (q) signalling events—PIK3CA—esophageal cancer	0.000235	0.00177	CbGpPWpGaD
Tolvaptan—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000234	0.00176	CbGpPWpGaD
Tolvaptan—Nausea—Methotrexate—esophageal cancer	0.000231	0.00199	CcSEcCtD
Tolvaptan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000231	0.00174	CbGpPWpGaD
Tolvaptan—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000228	0.00172	CbGpPWpGaD
Tolvaptan—ABCB1—HIF-1-alpha transcription factor network—NOS2—esophageal cancer	0.000226	0.0017	CbGpPWpGaD
Tolvaptan—CYP3A4—Biological oxidations—ADH7—esophageal cancer	0.000226	0.0017	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—ELMO1—esophageal cancer	0.000215	0.00162	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—ELMO1—esophageal cancer	0.000213	0.00161	CbGpPWpGaD
Tolvaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	0.00021	0.00159	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—AKAP13—esophageal cancer	0.00021	0.00158	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—AKAP13—esophageal cancer	0.000208	0.00157	CbGpPWpGaD
Tolvaptan—ABCB1—HIF-1-alpha transcription factor network—CREBBP—esophageal cancer	0.000203	0.00153	CbGpPWpGaD
Tolvaptan—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000199	0.0015	CbGpPWpGaD
Tolvaptan—CYP3A4—Biological oxidations—ADH1B—esophageal cancer	0.000198	0.00149	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000194	0.00146	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000192	0.00145	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—PDE4D—esophageal cancer	0.000192	0.00145	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—PDE4D—esophageal cancer	0.000191	0.00144	CbGpPWpGaD
Tolvaptan—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000187	0.00141	CbGpPWpGaD
Tolvaptan—CYP3A4—Biological oxidations—CYP26A1—esophageal cancer	0.000184	0.00139	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—GNG7—esophageal cancer	0.000183	0.00138	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—ANXA1—esophageal cancer	0.000182	0.00137	CbGpPWpGaD
Tolvaptan—CYP3A4—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000181	0.00137	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—GNG7—esophageal cancer	0.000181	0.00137	CbGpPWpGaD
Tolvaptan—AVPR2—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000181	0.00136	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—CASP8—esophageal cancer	0.000177	0.00133	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—XIAP—esophageal cancer	0.000171	0.00129	CbGpPWpGaD
Tolvaptan—CYP3A4—Biological oxidations—GSTO1—esophageal cancer	0.000171	0.00129	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—XIAP—esophageal cancer	0.00017	0.00128	CbGpPWpGaD
Tolvaptan—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	0.000169	0.00127	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—esophageal cancer	0.000166	0.00125	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CTNNA1—esophageal cancer	0.000162	0.00122	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CXCL2—esophageal cancer	0.000161	0.00121	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CTNNA1—esophageal cancer	0.000161	0.00121	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CXCL2—esophageal cancer	0.00016	0.0012	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	0.000158	0.00119	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.000157	0.00119	CbGpPWpGaD
Tolvaptan—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—esophageal cancer	0.000153	0.00115	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—PSME2—esophageal cancer	0.00015	0.00113	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—PSME1—esophageal cancer	0.00015	0.00113	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—ANXA1—esophageal cancer	0.00015	0.00113	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—PSME2—esophageal cancer	0.000149	0.00112	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—PSME1—esophageal cancer	0.000149	0.00112	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—ANXA1—esophageal cancer	0.000148	0.00112	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.000148	0.00111	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—SST—esophageal cancer	0.000146	0.0011	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—SST—esophageal cancer	0.000144	0.00109	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—NOTCH3—esophageal cancer	0.000142	0.00107	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—GHRL—esophageal cancer	0.000142	0.00107	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—NOTCH3—esophageal cancer	0.000141	0.00106	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—GHRL—esophageal cancer	0.000141	0.00106	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.00014	0.00106	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—FBXW7—esophageal cancer	0.000139	0.00105	CbGpPWpGaD
Tolvaptan—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	0.000139	0.00105	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—FBXW7—esophageal cancer	0.000138	0.00104	CbGpPWpGaD
Tolvaptan—ABCB1—HIF-1-alpha transcription factor network—EP300—esophageal cancer	0.000138	0.00104	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	0.000134	0.00101	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.000134	0.00101	CbGpPWpGaD
Tolvaptan—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	0.000133	0.001	CbGpPWpGaD
Tolvaptan—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	0.000131	0.000988	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	0.00013	0.000979	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.000128	0.000966	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.000128	0.000966	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—NOTCH2—esophageal cancer	0.000127	0.000958	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—NOTCH2—esophageal cancer	0.000126	0.000952	CbGpPWpGaD
Tolvaptan—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	0.000124	0.000937	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	0.000123	0.000926	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—TGFBR2—esophageal cancer	0.000113	0.00085	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—TGFBR2—esophageal cancer	0.000112	0.000844	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—SMAD4—esophageal cancer	0.000107	0.000805	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—SMAD4—esophageal cancer	0.000106	0.000799	CbGpPWpGaD
Tolvaptan—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	0.000106	0.000796	CbGpPWpGaD
Tolvaptan—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000104	0.000785	CbGpPWpGaD
Tolvaptan—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	9.94e-05	0.000749	CbGpPWpGaD
Tolvaptan—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	9.8e-05	0.000738	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—ABCC2—esophageal cancer	9.72e-05	0.000732	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—GNG7—esophageal cancer	8.82e-05	0.000665	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—HIF1A—esophageal cancer	8.74e-05	0.000659	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	8.72e-05	0.000657	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	8.68e-05	0.000654	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—HIF1A—esophageal cancer	8.68e-05	0.000654	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—BLVRB—esophageal cancer	8.67e-05	0.000653	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—SLC52A3—esophageal cancer	8.67e-05	0.000653	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—KDR—esophageal cancer	8.36e-05	0.00063	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—KDR—esophageal cancer	8.3e-05	0.000625	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—NOTCH1—esophageal cancer	7.87e-05	0.000593	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—NOTCH1—esophageal cancer	7.82e-05	0.000589	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	7.48e-05	0.000564	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—CA1—esophageal cancer	7.37e-05	0.000555	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—SLC10A2—esophageal cancer	7.37e-05	0.000555	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	7.27e-05	0.000548	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CREBBP—esophageal cancer	7.14e-05	0.000538	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	7.11e-05	0.000536	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CREBBP—esophageal cancer	7.09e-05	0.000534	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—EGFR—esophageal cancer	7.01e-05	0.000529	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—EGFR—esophageal cancer	6.96e-05	0.000525	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—CA2—esophageal cancer	6.74e-05	0.000508	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—PIK3CA—esophageal cancer	6.7e-05	0.000505	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—PIK3CA—esophageal cancer	6.66e-05	0.000502	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	6.42e-05	0.000484	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—NOS3—esophageal cancer	6.39e-05	0.000482	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—NOS3—esophageal cancer	6.34e-05	0.000478	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—ADH7—esophageal cancer	6.26e-05	0.000472	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—PLCE1—esophageal cancer	6.26e-05	0.000472	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	6.21e-05	0.000468	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—PIK3CA—esophageal cancer	6.09e-05	0.000459	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—PIK3CA—esophageal cancer	6.04e-05	0.000455	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—ERBB2—esophageal cancer	5.98e-05	0.00045	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—ERBB2—esophageal cancer	5.93e-05	0.000447	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	5.91e-05	0.000446	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—ADH1B—esophageal cancer	5.49e-05	0.000414	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	5.37e-05	0.000405	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—BLVRB—esophageal cancer	5.34e-05	0.000402	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—SLC52A3—esophageal cancer	5.34e-05	0.000402	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CCND1—esophageal cancer	5.28e-05	0.000398	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—TYMP—esophageal cancer	5.25e-05	0.000396	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CCND1—esophageal cancer	5.24e-05	0.000395	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	5.15e-05	0.000388	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CDKN1A—esophageal cancer	5.11e-05	0.000385	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—CYP26A1—esophageal cancer	5.11e-05	0.000385	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CDKN1A—esophageal cancer	5.07e-05	0.000382	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	5.04e-05	0.00038	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—ALOX15—esophageal cancer	4.98e-05	0.000375	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—EP300—esophageal cancer	4.86e-05	0.000366	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—EP300—esophageal cancer	4.83e-05	0.000364	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—GSTO1—esophageal cancer	4.75e-05	0.000358	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—TPI1—esophageal cancer	4.75e-05	0.000358	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—ALDOB—esophageal cancer	4.55e-05	0.000343	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—SLC10A2—esophageal cancer	4.54e-05	0.000342	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—CA1—esophageal cancer	4.54e-05	0.000342	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—GAPDH—esophageal cancer	4.38e-05	0.00033	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	4.37e-05	0.00033	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—CRABP1—esophageal cancer	4.34e-05	0.000327	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—MYC—esophageal cancer	4.24e-05	0.000319	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	4.23e-05	0.000319	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—MYC—esophageal cancer	4.21e-05	0.000317	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—CA2—esophageal cancer	4.15e-05	0.000313	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—EGFR—esophageal cancer	4.14e-05	0.000312	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—GNG7—esophageal cancer	4.13e-05	0.000311	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—EGFR—esophageal cancer	4.11e-05	0.00031	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—ALDH2—esophageal cancer	3.87e-05	0.000292	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—PLCE1—esophageal cancer	3.86e-05	0.000291	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—ADH7—esophageal cancer	3.86e-05	0.000291	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—GSTT1—esophageal cancer	3.68e-05	0.000277	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—CYP2A6—esophageal cancer	3.64e-05	0.000274	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—PIK3CA—esophageal cancer	3.6e-05	0.000271	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—PIK3CA—esophageal cancer	3.57e-05	0.000269	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—TP53—esophageal cancer	3.48e-05	0.000262	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—TP53—esophageal cancer	3.45e-05	0.00026	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—ENO1—esophageal cancer	3.45e-05	0.00026	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—PTGS1—esophageal cancer	3.45e-05	0.00026	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	3.45e-05	0.00026	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—PSME2—esophageal cancer	3.4e-05	0.000256	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—PSME1—esophageal cancer	3.4e-05	0.000256	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—ADH1B—esophageal cancer	3.38e-05	0.000255	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—TYMP—esophageal cancer	3.23e-05	0.000244	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—CYP26A1—esophageal cancer	3.15e-05	0.000237	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—ALOX15—esophageal cancer	3.07e-05	0.000231	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—CYP1B1—esophageal cancer	2.93e-05	0.000221	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—TPI1—esophageal cancer	2.93e-05	0.00022	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—GSTO1—esophageal cancer	2.93e-05	0.00022	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—ALDOB—esophageal cancer	2.8e-05	0.000211	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—CYP19A1—esophageal cancer	2.76e-05	0.000208	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—GAPDH—esophageal cancer	2.7e-05	0.000203	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—CRABP1—esophageal cancer	2.68e-05	0.000202	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—GNG7—esophageal cancer	2.54e-05	0.000192	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—HMOX1—esophageal cancer	2.52e-05	0.00019	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—ALDH2—esophageal cancer	2.38e-05	0.00018	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—GSTT1—esophageal cancer	2.27e-05	0.000171	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—CYP2A6—esophageal cancer	2.24e-05	0.000169	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—ENO1—esophageal cancer	2.13e-05	0.00016	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—PTGS1—esophageal cancer	2.13e-05	0.00016	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—PSME2—esophageal cancer	2.09e-05	0.000158	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—PSME1—esophageal cancer	2.09e-05	0.000158	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—CYP1B1—esophageal cancer	1.81e-05	0.000136	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—CYP19A1—esophageal cancer	1.7e-05	0.000128	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—CREBBP—esophageal cancer	1.61e-05	0.000122	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—HMOX1—esophageal cancer	1.55e-05	0.000117	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—ABCB1—esophageal cancer	1.49e-05	0.000112	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—NOS3—esophageal cancer	1.45e-05	0.000109	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—PTGS2—esophageal cancer	1.32e-05	9.96e-05	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—EP300—esophageal cancer	1.1e-05	8.29e-05	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—CREBBP—esophageal cancer	9.95e-06	7.5e-05	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—NOS3—esophageal cancer	8.9e-06	6.71e-05	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—PTGS2—esophageal cancer	8.14e-06	6.14e-05	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—PIK3CA—esophageal cancer	8.13e-06	6.13e-05	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—EP300—esophageal cancer	6.77e-06	5.11e-05	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—PIK3CA—esophageal cancer	5.01e-06	3.78e-05	CbGpPWpGaD
